The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 9-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.
As of today (2026-07-04), Gubra AS's 9-Day RSI is 45.51.
The industry rank for Gubra AS's 9-Day RSI or its related term are showing as below:
FRA:PI3's 9-Day RSI is ranked better than 63.36% of 1422
companies
in the Biotechnology industry
Industry Median: 51.47
vs FRA:PI3: 45.51
Gubra AS (FRA:PI3) 9-Day RSI Explanation
The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.
Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.
RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 9-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.
Gubra AS 9-Day RSI Related Terms
FRA:PI3 vs VRTX, REGN, ALNY: 9-Day RSI Comparison
For the Biotechnology subindustry, Gubra AS's 9-Day RSI, along with its competitors' market caps and 9-Day RSI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Gubra AS 9-Day RSI vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Gubra AS's 9-Day RSI distribution charts can be found below:
* The bar in red indicates where Gubra AS's 9-Day RSI falls into.
* Note that the formula uses a positive value for the average loss.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Gubra AS (FRA:PI3) has a 9-Day RSI of 45.51 as of Jul. 04, 2026. According to the industry distribution chart, Gubra AS ranks #521 out of 1422 companies in the Biotechnology industry, placing it in the top 36.6%.
Is Gubra AS's 9-Day RSI too high?
Gubra AS's current 9-Day RSI is 45.51. The Biotechnology industry median 9-Day RSI is 51.47. Gubra AS's value of 45.51 is 11.6% below this industry median. Based on the distribution chart, Gubra AS ranks #521 out of 1422 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Gubra AS has a GF Score™ of 73/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Gubra AS's 9-Day RSI compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Gubra AS ranks #521 out of 1422 companies for 9-Day RSI. This puts Gubra AS in the upper half of its industry. The industry median 9-Day RSI is 51.47. Gubra AS's value of 45.51 is 11.6% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 9-Day RSI for a Biotechnology company?
The median 9-Day RSI among Biotechnology companies is 51.47, based on 1,422 companies in the industry. Companies in the top quartile (top 25%) have a 9-Day RSI significantly above this median, while those in the bottom quartile fall well below. However, 9-Day RSI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Gubra AS's current 9-Day RSI of 45.51 is 11.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 9-Day RSI mean?
A high 9-Day RSI can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median 9-Day RSI is 51.47 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Gubra AS's current 9-Day RSI is 45.51. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gubra AS stock overvalued right now?
Based on GuruFocus' analysis, Gubra AS (FRA:PI3) is currently considered Possible Value Trap. The stock's GF Value™ is €372.36, compared to a current price of €44.00 — trading 88.2% below its estimated fair value. The current 9-Day RSI is 45.51 and 11.6% below the Biotechnology industry median of 51.47. Gubra AS's overall GF Score™ is 73/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 9-Day RSI calculated?
9-Day RSI is calculated from a company's financial statements. For Gubra AS (FRA:PI3), the current 9-Day RSI is 45.51 as of Jul. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Gubra AS (FRA:PI3) Overvalued in 2026?
Based on GuruFocus' analysis, Gubra AS stock appears to be undervalued.
The current stock price of €44.00 is trading 88.2% below its estimated GF Value™ of €372.36.
GuruFocus considers Gubra AS to be Possible Value Trap.
Key valuation signals for FRA:PI3:
9-Day RSI: 45.51
GF Value™: €372.36 vs. price of €44.00 (88.2% below fair value)
Industry Position: 11.6% below the Biotechnology median (#521 of 1422)
No single metric tells the full story. See the FRA:PI3 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Gubra AS is a specialized preclinical CRO and biotech company focused on peptide-based drug discovery within metabolic and fibrotic diseases. The company has two segments: Pre-clinical contract research (CRO), which derives maximum revenue and Biotech Segment. It derives maximum revenue from Pre-clinical contract research (CRO) segment. Geographically, the company operates in Europe, North America and Other regions.
73GF Score
Get the complete analysis for FRA:PI3
9-Day RSI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:PI3 has been successfully added to your 